Drug intelligence / Profile preview

MACUCIL

Development stage: Unknown
Lead developer: Martia Laboratories
Modality: Small Molecules
Administration: Oral

Overview

MACUCIL is an ophthalmic nutritional supplement developed and marketed by Martia Laboratories, an India-based eye care company. Formulated primarily as a tablet, it is categorized as an antioxidant supplement intended to support general eye health and provide nutritional defense against conditions such as macular degeneration. Although the specific active ingredient profile is not publicly detailed in primary marketing materials, it belongs to a broader product family that includes MACUCIL Kids Gummies and MACUCIL Syrup. As a nutraceutical, it is positioned for the maintenance of ocular function and the neutralization of free radicals in ocular tissues rather than as a primary pharmaceutical intervention.

Brand names: MACUCIL
Other names: Macucil

Beyond the preview

Go deeper on MACUCIL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MACUCIL.

Explore the full profile